多西他赛联合卡培他滨治疗晚期三阴性乳腺癌的疗效刍议

On the Efficacy of Docetaxel Combined with Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

目的研究晚期三阴性患者乳腺癌进行多西他赛联合卡培他滨的临床治疗效果。方法选取该院接收的50例晚期三阴性乳腺癌患者,该次实验研究的时间范围为2017年6月—2019年6月,采用抽签分组法将其分为联合治疗组与单一治疗组,联合治疗组患者进行多西他赛联合卡培他滨,单一治疗组患者采用常规的多西他赛单药进行治疗。将两组患者的治疗效果、治疗满意度以及不良反应、负面情绪改善情况、生活质量情况进行比较。结果联合治疗组患者的治疗效果优于单一治疗组,两组患者差异有统计学意义(χ^2=5.357,P=0.021),两组数据分别为24例、18例。联合治疗组患者的治疗满意度优于单一治疗组患者,差异有统计学意义(χ^2=5.357,P=0.021)。两组数据分别为24例、18例。两组患者的不良反应情况差异无统计学意义(χ^2=0.000,P=1.000)。两组不良反应发生例数均为1例。联合治疗组患者的负面情绪改善情况明显优于单一治疗组患者,两组数据分别为(50.14±2.58)分、(48.28±2.99)分;(44.14±2.39)分,(40.58±2.98)分,差异有统计学意义(t=10.790,11.536,P=0.000,0.000)。联合治疗组患者的生活质量情况明显优于单一治疗组患者,两组数据分别为(80.47±2.16)分,(89.99±2.04)分,差异有统计学意义(t=14.330,P=0.000)。结论晚期三阴性乳腺癌患者应用多西他赛联合卡培他滨的临床效果明显,可以明显提高疗效,增加患者的治疗满意度,提高患者生存质量,患者的不良反应可耐受。

Objective To study the clinical treatment effect of docetaxel combined with capecitabine in breast cancer of advanced triple-negative patients.Methods To select 50 patients with advanced triple-negative breast cancer received in the hospital,the time frame of this experimental study was from June 312017 to June 31,2019,they were divided into a combined treatment group and a single treatment group by lot drawing.The patients in the combined treatment group were treated with docetaxel and capecitabine,and the patients in the single treatment group were treated with conventional methods.Of docetaxel as a single drug.The treatment effect,treatment satisfaction and adverse reactions,improvement of negative emotions,and quality of life of the two groups of patients were compared.Results The treatment effect of the patients in the combined treatment group was better than that of the single treatment group.The difference between the two groups was significant(χ^2=5.357,P=0.021).The data of the two groups were 24 and 18 respectively.The treatment satisfaction of the patients in the combined treatment group was better than that in the single treatment group,and the difference between the groups was obvious(χ^2=5.357,P=0.021).The two sets of data are 24 persons and 18 persons respectively.There was no statistical difference in adverse reactions between the two groups of patients(χ^2=0.000,P=1.000).The number of adverse reactions in both groups was 1 person.The negative mood improvement of the patients in the combined treatment group was significantly better than that in the single treatment group.The data scores were(50.14±2.58)points、(48.28±2.99)points;(44.14±2.39)points,(40.58±2.98)points.The difference was statistically significant(t=10.790,11.536,P=0.000,0.000).The quality of life of the patients in the combined treatment group was significantly better than that in the single treatment group.The data between the two groups was(80.47±2.16)points,(89.99±2.04)points,the difference was statistically significant(t=14.330,P=0.000).Conclusion The clinical effect of docetaxel combined with capecitabine in patients with advanced triple-negative breast cancer is obvious,which can significantly improve the efficacy,increase the patient's treatment satisfaction,improve the patient's quality of life,and the patient's adverse reactions can be tolerated.